{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:04:49Z","timestamp":1789362289721,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Periorbital hyperpigmentation (POH) as the sole initial manifestation remains undescribed in patients with smoldering multiple myeloma (SMM) without amyloid deposition, and the coexistence of SMM with gastrointestinal stromal tumor (GIST) is exceptionally rare. We describe a 56-year-old male who was treated with imatinib for eight months after resection of a low-risk gastric GIST and developed bilateral symmetric POH. Workup revealed IgA \u03ba-type monoclonal gammopathy and 3% abnormal plasma cells on bone marrow aspiration. Further biopsies of bone marrow and abdominal wall fat excluded amyloid deposition. Therefore, a diagnosis of SMM (IgA \u03ba-type) was made. To the best of our knowledge, this is the first reported case of SMM presenting with isolated POH in the absence of light-chain (AL) amyloidosis and coexisting with a GIST. This case suggests that POH may represent a rare early cutaneous manifestation of SMM and may further broaden the recognized clinical spectrum of SMM.<\/jats:p>","DOI":"10.3389\/fonc.2026.1908738","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:34:43Z","timestamp":1789360483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Periorbital hyperpigmentation as the initial manifestation of smoldering multiple myeloma in a patient with coexisting gastrointestinal stromal tumor: a case report and narrative literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuze","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.06.025","article-title":"Risk stratification of patients diagnosed with gastrointestinal stromal tumor","volume":"39","author":"Joensuu","year":"2008","journal-title":"Hum Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1186\/s12885-024-13219-0","article-title":"Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","article-title":"Amyloidosis as a systemic disease in context","volume":"36","author":"Cuddy","year":"2020","journal-title":"Can J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/life13071518","article-title":"AL amyloidosis and multiple myeloma: a complex scenario in which cardiac involvement remains the key prognostic factor","volume":"13","author":"R\u00edos-Tamayo","year":"2023","journal-title":"Life"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae109","article-title":"Progressive hyperpigmentation and lentigines due to KIT variants improving with imatinib","volume":"191","author":"Liang","year":"2024","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220903364","article-title":"Hyperpigmentation due to imatinib: A rare case of cutaneous involvement","volume":"26","author":"Rehman","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/0378-6323.182387","article-title":"Imatinib induced melasma-like pigmentation: report of five cases and review of literature","volume":"82","author":"Ghunawat","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/0019-5154.164447","article-title":"Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia","volume":"60","author":"Balasubramanian","year":"2015","journal-title":"Indian J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0985","article-title":"Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth","volume":"5","author":"Ran","year":"2015","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081940","article-title":"Synchronous\/metachronous multiple primary Malignancies: Review of associated risk factors","volume":"12","author":"Pan","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i13.2011","article-title":"Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: A case report","volume":"13","author":"Tzilves","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad377","article-title":"Correlation between second and first primary cancer: Systematic review and meta-analysis of 9 million cancer patients","volume":"111","author":"Wang","year":"2024","journal-title":"Br J Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72132-4","article-title":"Plasmacytoma manifesting as recurrent cellulitis and hematic cyst of the orbit","volume":"122","author":"Rappaport","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"bcr2016219010","DOI":"10.1136\/bcr-2016-219010","article-title":"Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis","volume":"2017","author":"Vilcassim","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3116","article-title":"Periorbital xanthoma-like amyloidosis in a patient with multiple myeloma-associated systemic amyloidosis","volume":"29","author":"Kikuchi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15807","article-title":"Diffuse plane xanthomas as the first manifestation of multiple myeloma","volume":"23","author":"Koutra","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2019.31.2.238","article-title":"Diffuse normolipemic plane xanthomatosis with immunoglobulin-lambda light-chain deposition in a patient with multiple myeloma","volume":"31","author":"Lee","year":"2019","journal-title":"Ann Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.111170","article-title":"Necrobiotic xanthogranuloma associated with IgG kappa smoldering myeloma presenting as vision-threatening orbital disease: clinical response to plasma cell-directed therapy","volume":"18","author":"Cheema","year":"2026","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/1319-4534.301163","article-title":"Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis","volume":"34","author":"Bouattour","year":"2020","journal-title":"Saudi J Ophthalmol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908738\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:34:54Z","timestamp":1789360494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908738\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1908738"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1908738","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1908738"}}